| Hypertensive disease
Nexiclon XR vs Tribenzor
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Nexiclon Xr vs Tribenzor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTribenzor has a higher rate of injection site reactions vs Nexiclon Xr based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tribenzor but not Nexiclon Xr, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nexiclon Xr
Tribenzor
At A Glance
Oral
Once daily
Centrally active alpha-adrenergic agonist
Oral
Daily
ARB / CCB / thiazide diuretic
Indications
- Hypertensive disease
- Hypertensive disease
Dosing
Hypertensive disease Initiate at 0.17 mg once daily at bedtime; titrate by 0.09 mg once daily at weekly intervals as needed; usual range 0.17-0.52 mg once daily.
Renal Impairment End-stage kidney disease on dialysis: start at 0.09 mg/day and titrate slowly; moderate to severe impairment not on dialysis: initiate at standard dose and titrate slowly with monitoring for bradycardia, sedation, and hypotension.
Hypertensive disease Once daily; dosage may be increased in 2-week intervals as needed; maximum recommended dose is 40/10/25 mg; dose selection should be individualized based on previous therapy.
Contraindications
- Known hypersensitivity to clonidine
- Anuria
- Hypersensitivity to any component of Tribenzor or to other sulfonamide-derived drugs
- Co-administration of aliskiren in patients with diabetes
Adverse Reactions
Most common (>=10%) Dry mouth, drowsiness, dizziness, constipation, sedation
Serious Withdrawal syndrome, allergic reactions
Most common (>=2%) Dizziness, peripheral edema, headache, fatigue, nasopharyngitis, muscle spasms, nausea, upper respiratory tract infection, diarrhea, urinary tract infection, joint swelling
Postmarketing Angioedema, anaphylactic reactions, rhabdomyolysis, acute renal failure, sprue-like enteropathy, hyperkalemia, alopecia, pruritus, urticaria, gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder, non-melanoma skin cancer (hydrochlorothiazide)
Pharmacology
Clonidine stimulates alpha-adrenoreceptors in the brain stem, reducing sympathetic outflow from the CNS and decreasing peripheral resistance, renal vascular resistance, heart rate, and blood pressure.
Triple-combination antihypertensive; olmesartan medoxomil selectively blocks angiotensin II AT1 receptors in vascular smooth muscle, amlodipine inhibits transmembrane calcium ion influx into vascular and cardiac smooth muscle, and hydrochlorothiazide promotes renal excretion of sodium and chloride to reduce intravascular volume.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nexiclon Xr
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (9/12)
Tribenzor
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Nexiclon Xr
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Tribenzor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Nexiclon Xr
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (1/3) · Qty limit (1/3)
Tribenzor
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Nexiclon Xr.
No savings programs available for Tribenzor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Nexiclon XrView full Nexiclon Xr profile
TribenzorView full Tribenzor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.